Adam Esq - Cyteir Therapeutics G Counsel
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
Insider
Adam Esq is G Counsel of Cyteir Therapeutics
| Age | 38 |
| Phone | 857 285 4140 |
| Web | https://cyteir.com |
Cyteir Therapeutics Management Efficiency
The company has Return on Asset of (0.145) % which means that on every $100 spent on assets, it lost $0.145. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2381) %, meaning that it generated no profit with money invested by stockholders. Cyteir Therapeutics' management efficiency ratios could be used to measure how well Cyteir Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cyteir Therapeutics has 889 K in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Cyteir Therapeutics has a current ratio of 19.55, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Cyteir to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Andreas EMBA | Molecular Partners AG | 58 | |
| Richard Goold | Lyell Immunopharma | 64 | |
| MD MPH | MediciNova | 56 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| James Trager | Nkarta Inc | 61 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| James JD | Eliem Therapeutics | 58 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| David MD | Nuvation Bio | 54 | |
| Michele MBA | Prelude Therapeutics | N/A | |
| Bernard JD | Sana Biotechnology | 69 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| MBA MD | Generation Bio Co | 55 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Peggy Scherle | Prelude Therapeutics | 62 | |
| Hing Wong | HCW Biologics | 70 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| BS CMAR | Champions Oncology | N/A | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 |
Cyteir Therapeutics Leadership Team
Elected by the shareholders, the Cyteir Therapeutics' board of directors comprises two types of representatives: Cyteir Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyteir. The board's role is to monitor Cyteir Therapeutics' management team and ensure that shareholders' interests are well served. Cyteir Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyteir Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Esq, G Counsel | ||
| Markus MD, CEO President | ||
| Paul Secrist, Chief Officer | ||
| Gale Cohen, VP HR | ||
| Lisa Hayes, VP Communications | ||
| Joseph Zakrzewski, Independent Chairman | ||
| Timothy Romberger, Independent Director | ||
| Andrew Gengos, Chief Sec | ||
| Kevin Mills, CoFounder | ||
| David Gaiero, CFO Treasurer |
Cyteir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyteir Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |